NRSN logo

NRSN
NeuroSense Therapeutics Ltd

3,566
Mkt Cap
$25.81M
Volume
96,899.00
52W High
$2.60
52W Low
$0.63
PE Ratio
-1.21
NRSN Fundamentals
Price
$0.708
Prev Close
$0.73
Open
$0.73
50D MA
$0.8345
Beta
0.76
Avg. Volume
179,128.45
EPS (Annual)
-$0.4366
P/B
6.37
Rev/Employee
$0.00
$19.55
Loading...
Loading...
News
all
press releases
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Granted Brazilian Patent Covering PrimeC Composition NeuroSense Granted Brazilian Patent Covering PrimeC Composition PR Newswire CAMBRIDGE, Mass., April 6, 2026 Patent Protection Through...
PR Newswire·11d ago
News Placeholder
More News
News Placeholder
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding...
PR Newswire·14d ago
News Placeholder
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PR Newswire...
PR Newswire·17d ago
News Placeholder
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data...
PR Newswire·24d ago
News Placeholder
PrimeC New Data to Be Presented at AD/PD 2026 Conference
PrimeC New Data to Be Presented at AD/PD 2026 Conference PrimeC New Data to Be Presented at AD/PD 2026 Conference PR Newswire CAMBRIDGE, Mass., March 18, 2026 Dr. Christian Lunetta to Present 'From...
PR Newswire·30d ago
News Placeholder
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity JAMA Neurology Publishes Results from PARADIGM Phase...
PR Newswire·1mo ago
News Placeholder
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PR Newswire CAMBRIDGE...
PR Newswire·1mo ago
News Placeholder
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS NeuroSense Announces Statistically Significant 65...
PR Newswire·2mo ago
News Placeholder
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering...
PR Newswire·2mo ago
News Placeholder
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., Jan. 21, 2026 Patent protection...
PR Newswire·3mo ago
<
1
2
...
>

Latest NRSN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.